Summary

for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started

Description

Summary

This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.

Official Title

Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Details

This protocol will allow expanded access of ponatinib to patients ≥18 years with CML or Ph+ALL who have failed all available treatment options. Patients with chronic (CP) or accelerated phase (AP) CML must be previously treated with and resistant or intolerant to imatinib, dasatinib and nilotinib or develop the T315I mutation after any tyrosine kinase inhibitor (TKI) therapy. Patients with blast phase (BP) CML and Ph+ ALL must be previously treated with and resistant or intolerant to imatinib and dasatinib or develop the T315I mutation after any TKI therapy. No formal analysis will be performed on any data obtained. Safety information will be collected and adverse events will be tabulated for reporting purposes only.

Keywords

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Ponatinib Tyrosine kinase inhibitor Leukemia Leukemia, Myeloid Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Philadelphia Chromosome

Eligibility

For people ages 18 years and up

Main Inclusion Criteria:

  1. CP-CML and AP-CML patients previously treated with and resistant or intolerant to imatinib, dasatinib and nilotinib or those who developed the T315I mutation after any TKI therapy. BP-CML and Ph+ ALL patients previously treated with and resistant or intolerant to imatinib and dasatinib or those who developed the T315I mutation after any TKI therapy.
  2. Patients must be ≥ 18 years old.
  3. Provide written informed consent.
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  5. Men and women of childbearing potential must agree to effective contraception from the time of signing informed consent through the Follow-up Visit, approximately 30 days after last dose of ponatinib.

Main Exclusion Criteria:

Patients are not eligible for participation in the study if they meet any of the following

exclusion criteria:

  1. Are eligible for an ongoing and accessible clinical trial of ponatinib
  2. Have not adequately recovered from AEs due to agents previously administered
  3. Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.
  4. Have previously been treated with ponatinib.
  5. Have significant or active cardiovascular disease, specifically including, but not restricted to:
  6. Myocardial infarction within 3 months prior to first dose of ponatinib,
  7. History of clinically significant atrial arrhythmia or any ventricular arrhythmia,
  8. Unstable angina within 3 months prior to first dose of ponatinib,
  9. Congestive heart failure within 3 months prior to first dose of ponatinib.
  10. Have abnormal QTcF (> 450 ms for males or > 470 ms for females)
  11. Have a significant bleeding disorder unrelated to CML or Ph+ ALL.
  12. Have a history of pancreatitis or alcohol abuse
  13. Have elevated amylase or lipase (> 1.5 x ULN for institution) at entry.
  14. . Have inadequate hepatic function or any of the following:
  15. Total bilirubin > 1.5 x ULN for institution at entry
  16. Alanine aminotransferase and aspartate aminotransferase > 2.5 x ULN for institution at entry
  17. Prothrombin time >1.5 x ULN for institution at entry
  18. . Have inadequate renal function or serum creatinine > 2.5 x ULN for institution at entry
  19. . Have uncontrolled hypertriglyceridemia or triglycerides > 450 mg/dL at entry.
  20. . Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of orally administered ponatinib.
  21. . Women who are pregnant or lactating.
  22. . Underwent major surgery within 14 days prior to the first dose of ponatinib.
  23. . Have ongoing or active infection (including known history of human immunodeficiency virus [HIV], hepatitis B virus [HBV], or hepatitis C virus [HCV]).
  24. . Suffer from any condition or illness that, in the opinion of the Investigator would compromise patient safety or interfere with the evaluation of the safety of the study drug.

Locations

  • Moores UCSD Cancer Center, Site #165
    La Jolla California 92093 United States
  • Southern California Permanente Medical Group, Site #161
    San Marcos California 92069 United States

Details

Status
not accepting new patients
Start Date
Sponsor
Ariad Pharmaceuticals
ID
NCT01592136
Study Type
Expanded Access
Last Updated